Have your say
The Ministry for Primary Industries (MPI) invites comment on MPI’s risk analyses and risk management strategy for Mycoplasma bovis (M. bovis) in bovine germplasm (semen and embryos).
This is a non-statutory public consultation on the science, the risk assessments, the risk management options, and the feasibility of their application to effectively manage the biosecurity risks associated with M. bovis in bovine semen and embryos. Full details are in the documents.
This consultation will run from 25 September to 5 November 2019. It is in addition to a future consultation of the import health standards, which will require the CTO (chief technical officer) to consider all obligations of the Biosecurity Act 1993, including consistency with the SPS (the Agreement on the Application of Sanitary and Phytosanitary Measures) and WTO (World Trade Organization) obligations.
Mycoplasma bovis risk management in bovine germplasm [PDF, 882 KB]
Rapid risk assessments
Mycoplasma bovis in bovine semen [PDF, 520 KB]
Making your submission
Email your feedback by 5pm on 5 November 2019 to email@example.com
Make sure you include in your submission:
- the title of the consultation document in the subject line of your email
- your name and title
- your organisation's name (if you're submitting on behalf of an organisation)
- your contact details (for example, phone number, address and email).
While we prefer email, you can send your submission by post to:
Ministry for Primary Industries
PO Box 2526
All submissions received by the closing date will be considered. MPI may hold late submissions on file for consideration when the IHS undergoes consultation in 2020.
Submissions are public information
Note that any submission you make becomes public information. People can ask for copies of submissions under the Official Information Act 1982 (OIA). The OIA says we have to make submissions available unless we have a good reason for withholding it. That is explained in sections 6 and 9 of the OIA.
Tell us if you think there are grounds to withhold specific information in your submission. Reasons might include that it's commercially sensitive or it's personal information. However, any decision MPI makes to withhold information can be reviewed by the Ombudsman, who may tell us to release it.